Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kennon Miller

Urology E Providence, RI Medical Doctor

NPI 1689786725 CMS profile 349348

450 Veterans Memorial Pkwy, Building 14, E Providence, RI 02914

Open in the dashboard

General payments

$2,698

52 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kennon Miller of E Providence, RI is reported in the CMS Open Payments database as having received $2,698 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36 1
2024 General $94 2
2023 General $157 4
2022 General $173 3
2021 General $111 3
2020 General $18 1
2019 General $2,109 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kennon Miller
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Kennon Miller were reported at $36. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Kennon Miller Urology median Middle half National median
2019 $2,109 $480 $147–$1,201 $163
2020 $18 $246 $87–$645 $114
2021 $111 $358 $111–$1,000 $132
2022 $173 $476 $143–$1,263 $149
2023 $157 $560 $168–$1,461 $160
2024 $94 $563 $170–$1,464 $164
2025 $36 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,793 24 payments
  2. Coloplast Corp $494 16 payments
  3. Teleflex LLC $146 1 payment
  4. Pfizer Inc. $72 3 payments
  5. Dornier MedTech America, Inc $55 1 payment
  6. Astellas Pharma US Inc $46 3 payments
  7. Laborie Medical Technologies Corp. $36 1 payment
  8. Ferring Pharmaceuticals Inc. $20 1 payment
  9. Mission Pharmacal Company $19 1 payment
  10. Smith+Nephew, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,695 38 payments
  2. Travel and Lodging $881 6 payments
  3. Education $121 8 payments
Products named General payments · program years 2019–2025
  1. AMS $1,095 10 payments
  2. General Therapies $289 2 payments
  3. TITAN $243 3 payments
  4. UroLift System $146 1 payment
  5. SPEEDICATH $121 8 payments
  6. XTANDI $118 6 payments
  7. VIRTUE $107 3 payments
  8. AMS 700 $94 2 payments
  9. GENERAL MALE SUI $88 1 payment
  10. TOVIAZ $72 3 payments
  11. Other $306 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

562

Median for Urology: 1,053

Drug cost

$47,440

Median for Urology: $101,464

Branded share of claims

46.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 35 $26,313
Myrbetriq Mirabegron Brand 26 $11,630
Oxybutynin Chloride Er Oxybutynin Chloride Brand 64 $1,893
Tamsulosin Hcl Generic 94 $1,720
Tolterodine Tartrate Er Tolterodine Tartrate Brand 18 $1,094
Solifenacin Succinate Generic 17 $803
Trospium Chloride Generic 11 $665
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 90 $641
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 15 $569
Oxybutynin Chloride Generic 33 $566

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$51,461

Medicare's payments for the services billed

Medicare patients

178

Average age 76

Services billed

621

34 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Cancer 47%
Chronic kidney disease 46%
Diabetes 37%
Ischemic heart disease 37%
Atrial fibrillation 34%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record